Long-term sequelae of treatment for testicular germ cell tumours. by Bissett, D. et al.
Br. J. Cancer (1990), 62, 655 659 C) Macmillan Press Ltd.,
Long-term sequelae of treatment for testicular germ cell tumours
D. Bissett', L. Kunkelerl, L. Zwanenburg', J. Paul', C. Gray2, I.R.C. Swan3, D.J. Kerr' &
S.B. Kaye'
'CRC Department ofMedical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; 2Institute ofBiochemistry, and
3University Department ofOtolaryngology, Royal Infirmary, Glasgow, UK.
Summary Seventy-four patients previously treated in our department for germ cell tumour of the testis
underwent a series of tests to determine the frequency of long-term therapeutic complications. All had received
cisplatin-based chemotherapy as part of their treatment. There was a significant deterioration in renal function
throughout the group. Eighteen (24%) had supine blood pressure greater than systolic 140 mmHg or diastolic
90 mmHg after treatment but hypertension did not correlate with renal impairment. Raynaud's phenomenon
was common after chemotherapy (26/74) as was persistent sensory neuropathy (23/74). Although 34% had
testosterone levels below the normal range, only six patients had a low free testosterone index with one testis
still in situ; 18 patients have fathered children after chemotherapy. Approximately half of the patients
completed a psychosexual questionnaire and some 30% of them admitted to sexual problems which they
attributed to their treatment. Long-term sequelae of cisplatin-based chemotherapy for testicular malignancy
are frequent and persistent, and follow-up of these patients should include prospective measurement of
changes in blood pressure.
Over the past 20 years there has been a dramatic change in
both the incidence of germ cell malignancy - this has risen
three-fold to the current figure of 3-4 per 100,000 males per
annum (Boyle et al., 1987) - and its long-term survival,
which currently stands at about 85% (Graham et al., 1988).
The combination of cisplatin, vinblastine and bleomycin was
introduced in the 1970s for disseminated testicular teratoma,
and in the 1980s etoposide was shown to be superior to
vinblastine in this combination (Williams et al., 1987). How-
ever, cisplatin remains the essential element of therapy and
much effort has since been focused on reducing the toxicity
of this regimen while maintaining its efficacy (Kantoff et al.,
1988).
As the number of survivors of these tumours has risen,
attention has been drawn to the late effects of the
chemotherapy used, in particular cisplatin (Fossa et al., 1986;
Roth et al., 1988). Commonly recognised are chronic renal
impairment (Bosl et al., 1986; Meijer et al., 1983; Vogelzang
et al., 1985), Raynaud's phenomenon (Vogelzang et al.,
1981), peripheral neuropathy (Thompson et al., 1984), high
frequency hearing loss and tinnitus (Vermorken et al., 1983)
and infertility (Drasga et al., 1983). The implication of
chemotherapy in major vascular occlusions (Samuels et al.,
1987), second malignancy (Roth et al., 1988) and hyperten-
sion is less clearly defined.
In this study we report on long-term toxicity in a group of
74 patients with testicular cancer treated in our unit over the
past decade.
Materials and methods
One hundred and twenty patients who had been referred for
treatment for testicular malignancy between 1978 and 1988 at
Gartnavel General Hospital, were invited to participate in the
study. All patients were in complete remission and had nor-
mal serum AFP and HCG. Seventy-four patients who had
received chemotherapy agreed to attend and from their case
records were culled salient pre-chemotherapy details includ-
ing blood pressure, creatinine clearance, biochemical profile
and ECG. Their characteristics are summarised in Table I.
Fifteen patients had also received radiotherapy to abdominal
nodal disease after chemotherapy. One patient had a formal
retroperitoneal lymph node dissection (RPLND) and 14
others had surgical resection of residual masses post-
chemotherapy.
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Table I Summary of patients' characteristics and pathology
Number of patients 74
Age (years) median 30
range 16-63
Duration of follow-up
(months) median 52
range 13-125
Number of % of
Pathology patients total
Seminoma 8 11
Malignant teratoma undifferentiated 30 41
Malignant teratoma intermediate 27 36
Malignant teratoma trophoblastic 6 8
Mixed teratoma and seminoma 1 1
Teratoma differentiated 2 3
On the study day venepunctures were performed between
08.00 and 09.00 so that plasma renin and aldosterone levels
could be reproducibly measured. A computerised proforma-
guided case history was taken including details of short and
long-term chemotherapy toxicity; a general health enquiry
with emphasis on cigarette smoking, alcohol consumption,
and cardiovascular and renal disease; a family history asking
specifically about hypertension and ischaemic heart disease.
Patients were asked specifically about Raynaud's
phenomenon, 'Do your fingers become white and painful in
the cold? Occasionally, frequently, or always?', and if they
experienced numbness or tingling in their hands or feet. A
full physical examination followed including objective assess-
ment of any sensory or motor deficit. Erect and supine blood
pressure were measured 3 times with a standard mercury
sphygmomanometer during the examination and the diastolic
pressure taken at the fourth Korotkov sound. The mean
supine blood pressure was used in the analysis of results.
Twelve-lead electrocardiography was performed and blood
and a 24 h collection of urine sent for analysis. Biochemical
profile was measured on a Technicon SMAC Analyser and
serum magnesium assayed with a dye binding method using
Calmagite/EDTA at Gartnavel General Hospital. Serum
aldosterone was assayed with a DPC 'coat-a-count' radioim-
munoassay, plasma renin with a Serono Renin Maia Kit, and
serum FSH, LH, testosterone, and androstenedione with an
'in-house' radioimmunoassay at Glasgow Royal Infirmary.
The same department also measured 24h urinary sodium,
creatinine and aldosterone. Creatinine clearance was cal-
culated using the serum and 24 h urine creatinine values.
Patients' hearing was screened by pure-tone audiometry
using a Peters AP32 portable audiometer with sound-
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reducing headphones in a quiet clinic room. Air conduction
thresholds were assessed at 0.5, 1, 2, 4 and 8 kHz. All
patients with any single pure-tone threshold worse than
20 dB HL were invited to attend for formal audiometry,
where pure-tone air and bone conduction thresholds were
assessed using a standard method (British Society of
Audiology, 1981) with masking as required (Coles & Priede,
1970).
On leaving the clinic each patient was given a psychosexual
questionnaire to complete and return anonymously. This was
an 'in-house' questionnaire in which patients were asked to
record current sexual problems, their relation to previous
medical treatment, body image problems, and any other
psychological difficulties experienced in relation to their treat-
ment.
Statistical methods of analysis are the Wilcoxon signed
rank test where pre- and post-chemotherapy measurements
on the same patient are compared (e.g. Table III); the
Mann-Whitney U test where measurements on different
patients are compared (e.g. Table IV); and Spearman's rank
correlation coefficient to detect association between two con-
tinuous variables. In the figures the line drawn is derived
from simple linear regression methods.
Results
Chemotherapy doses
Total doses of drug received are listed for the 5 agents
involved in Table II.
Renalfunction
There was a significant deterioration in renal function after
chemotherapy with a fall in creatinine clearance (Table III)
but serum magnesium levels were normal (post-chemotherapy
median 0.83 mmol 1'- range 0.64-1.12 mmol 1-'). The rise in
serum creatinine correlated weakly with the dose of cisplatin
received (Spearman's rank correlation coefficient= 0.25,
0.01 <P <0.05) (Figure 1). All patients had saline hydration
before and after cisplatin but information regarding other
potentially nephrotoxic drugs given during or after the
chemotherapy was not available.
Bloodpressure
Eighteen (24%) of the 74 patients were hypertensive by
WHO criteria (blood pressure systolic > 140 or diastolic
>90 mmHg) at follow-up. Although this did not represent a
significant rise compared with 13 high pre-chemotherapy
measurements, these original measurements were single re-
cordings taken on admission for chemotherapy by a number
of different nurses using a selection of mercury sphyg-
momanometers. Post-chemotherapy hypertension did not
correlate with serum creatinine or creatinine clearance but
hypertensive patients tended to be older (P = 0.07). It did
not correlate with pre-chemotherapy hypertension, a family
history of hypertension, or smoking; nor could we detect an
alteration in the renin-angiotensin-aldosterone axis. There
was no correlation between drug dose and the development
of hypertension (Table IV).
Table II Cumulative chemotherapy doses
Total dose (mgm-2)
Drug Median Range No. ofpatients
Cisplatin 400 80- 780 74
Vincristine 4 1- 28 19
VP16 1210 480-2800 50
Vinblastine 39 10- 89 28
Total dose (mg)
Bleomycin 345 25- 600 61
Table HI Renal function
Pre-chemotherapy Post-chemotherapy P
Serum creatinine 84 (54-124) 95 (43-171) <0.001
(mmol 11)
Creatinine clearance 130 (41-233) 101.5 (49-331) 0.001
(ml/min-')
Each entry is median (min.-max.). Pvalue from Wilcoxon signed
rank sum test.
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Figure 1 Correlation of rise in serum creatinine (post- minus
pre-treatment value) with dose of cisplatin received.
Table IV Hypertension after treatment
Yes No P
Age at survey 41 (20-68) 32 (19-51) 0.07
(years) n = 18 n = 56
Creatinine 98 (49-158) 102 (63-331) 0.49
clearance (ml min-') n = 15 n = 41
Serum 96 (88-171) 95 (43-155) 0.23
creatinine (mmoll') n = 18 n = 55
Serum 14 (5-31) 21 (1-147) 0.09
renin activity n = 18 n = 55
Serum 431 (176-678) 443 (168-999) 0.55
aldosterone (pmol -') n = 18 n = 56
Urinary 30 (17-84) 33 (12-74) 0.73
aldosterone (nmol 24h-') n = 15 n =42
Urinary 236 (96-375) 187 (84-378) 0.03
sodium (mmol 24h-') n = 15 n =41
Total cisplatin 400 (82-611) 400 (120-783) 0.69
(mgm-2) n=18 n=56
Time since chemotherapy 5.0 (1.4-8.8) 4.2 (1.1-10.3) 0.87
(years) n = 18 n = 56
Each entry is median (min.-max.). Pvalue from Mann-Whitney
U test.
No patient had ECG changes of left ventricular hyper-
trophy but 4 patients did have symptomatic ischaemic heart
disease and 2 had ECG evidence of previous myocardial
infarction.
Raynaud'sphenomenon
Raynaud's phenomenon was common, occurring in 33 out of
74 patients; 14 had frequent attacks. All patients with vaso-
spastic symptoms had received cisplatin, bleomycin, and a
vinca alkaloid. There was no apparent relationship between
the frequency of Raynaud's phenomenon and cumulative
drug dose nor with cigarette smoking.GERM CELL TUMOUR SEQUELAE 657
Peripheral neuropathy
Persistent sensory neuropathy with digital paraesthesiae or
numbness had occurred during or soon after chemotherapy
in 37 out of 74 patients but persisted in 23 (mean duration of
follow-up 62 months). Six patients had persistent motor dys-
function with difficulty writing and fastening buttons and 1
had evidence of autonomic neuropathy with symptomatic
postural hypotension, a measured fall in diastolic blood pres-
sure of 20 mmHg from supine to erect, and impotence. There
was a degree of cross-correlation of toxicity: 5/6 patients with
severe frequent episodes of vasospasm also had symptomatic
neuropathy. Again there was no demonstrable relationship
with drug dosage.
Hearing
Sixty patients who had received cisplatin had screening
audiometry carried out; 28 were found to have normal hear-
ing (no threshold worse than 20 dB HL).
Of the 32 patients who failed the screening audiometry, 26
attended for full audiometry. In nine of these 26, hearing
thresholds were found to be normal (20 dB HL or better), and
in a further one individual the hearing impairment was con-
ductive due to chronic otitis media. One of the six patients
who failed to attend for full audiometry had a unilateral
conductive hearing impairment. Thus 21 patients were
identified as having a sensorineural hearing impairment on the
basis of formal audiometry or, if this was not available (five
patients), of the screening audiometry. Seventeen had bilateral
impairment; in five this was only detectable at 8 kHz; in seven
the thresholds at 4 kHz and 8 kHz were affected; five had
impairment in the speech frequency range. Four patients had a
unilateral impairment detected at only 4 and 8 kHz.
Eleven of the 21 patients with hearing loss also had symp-
tomatic peripheral neuropathy. There was no significant
difference in total dose of cisplatin between those with nor-
mal hearing and those with hearing impairment.
Sex hormone levels
Twenty-five of 74 patients had serum testosterone levels
,<9nmol/1-' (normal range 11-36nmol/ 1-) but two of
these patients had bilateral orchidectomy and had undectable
testosterone levels; these were not assessed further. FSH and
LH levels were normal in the patients with normal circulating
testosterone concentrations but of the 23 patients with low
testosterone levels only 14 had elevated FSH and LH concen-
trations. The sex hormone binding globulin concentration
was measured in these 23 patients and the free testosterone
index estimated:
Free testosterone
serum testosterone (nmol/ll') x 100 index =
sex hormone binding globulin (nmol/P1)
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Figure 2 Correlation of post-chemotherapy FSH level and dose
of cisplatin received.
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Figure 3 Correlation of post-chemotherapy LH level and dose
of cisplatin received.
Only six patients had low free testosterone indices and all of
these had elevated levels of FSH and LH. The remaining 19
patients with low serum testosterone had free testosterone
indices in the normal range (established in 65 normal
volunteers by the Department of Biochemistry, Glasgow
Royal Infirmary, mean ± 2 s.d. = 16-23). Elevation of FSH
and LH correlated with total dose of cisplatin (Spearman's
rank correlation coefficient 0.37 and 0.32 respectively,
P <0.01) (Figures 2 and 3) and the age of the patient
(correlation coefficients 0.25 and 0.28, P <0.05) (Figures 4
and 5). The association of patient age and cisplatin dose is
weak (correlation coefficient 0.08) suggesting that cisplatin
dose and age have independent effects on FSH and LH.
Serum testosterone showed no statistically significant associa-
tion with cisplatin dose or age of patient (Figures 6 and 7)
and none of these endocrine changes seem to be related to
the time elapsed since chemotherapy.
A total of 18 (24%) men fathered children after
chemotherapy and none of these had significant congenital
abnormalities. We did not measure sperm counts nor do we
know how many patients had wished but failed to father
children.
Psychosexual
Only 33 (44%) returned the psychosexual questionnitire but
one third ofthese admitted sexual problems, either impotence
of ejaculatory failure or both and attributed to their treat-
ment. Alteration of 'body image' was not reported but at
least 18 patients (24%) had sought medical trektment for
other psychological problems since their chemotherapy,
usually anxiety or depressive states.
Discussion
Acute renal damage was recognised early in the development
of cisplatin, with both reduced GFR and tubular electrolyte
loss (Meijer et al., 1983). It appears that the fall in GFR
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Figure 5 Post-chemotherapy LH vs age at time of chemo-
therapy.
persists after the cessation of chemotherapy (Hamilton et al.,
1988), but tubular function returns to normal usually within
1 year ( Fjeldborg et al., 1986). This permanent deterioration
in renal function has not been linked with hypertension even
when associated with raised plasma renin and aldosterone
levels (Bosl et a!., 1986). We observed a definite deterioration
of renal function in our patients but this did not correlate
with the development of hypertension. No' valid comparison
can be made between the pre- and post-chemotherapy blood
pressure values as the pre-treatment levels were single
measurements made by different nurses using a number of
sphygmomanometers in patients under considerable stress
anticipating their firgt chemotherapy for testicular cancer. We
do believe that post-chemotherapy hypertension in 24% of
our patients is of considerable concern and that further
prospective study of cisplatin effects on blood pressure are
required. Renovascular malignant hypertension has been de-
scribed after chemotherapy with PVB but occurred only 3
months after chemotherapy (Ha'rrell et al., 1982).
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Figure 7 Post-chemotherapy serum testosterone vs age at time of
chemotherapy.
Raynaud's phenomenon is the commonest vascular toxicity
of these chemotherapy regimens, reported in up to 40% of
patients (Vogelzang et a!., 1981), but remains poorly under-
stood. Although originally a synergistic effect of bleomycin
and vinblastine was thought to contribute to this toxicity,
cisplatin also has been implicated (Vogelzang et a!., 1985).
Indeed platinum-induced hypomagnesaemia has been sug-
gested as the cause of vasospasm but this seems unlikely as
cold-intolerance tends to persist while mansum levels
return to normal. We have not found a relationship to drug
dosage and have not confirmed the previously reported
association with smoking.
Recent interest has focused on large vessel occlusions
associated with chemotherapy for testicular mlignancy and
coronary artery vasospasm has been found in a few patients
(Doll et a!., 1986; Samuels et a!., 1987). However, the fre-,
quent presence of other risk factors for coronary artery
disease raises doubts about the role of chemotherapy. Cer-
tainly we draw no conclusions from our four men with
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ischaemic heart disease given that all smoked and had family
histories of ischaemic heart disease.
Neuropathy occurs in the majority of patients receiving
chemotherapy for testicular germ cell tumours despite the
hope that substituting etoposide for vinblastine would reduce
its frequency (Williams et al., 1987). Cisplatin is the prime
cause and has been found in peripheral nerves at concentra-
tions comparable to those achieved in tumour, causing
axonal degeneration and secondary myelin breakdown
(Thompson et al., 1984). The clinical picture is of impaired
distal sensation especially vibration sense, loss of reflexes,
and troublesome paraesthesiae which lessen after cessation of
chemotherapy but tend to persist for prolonged periods.
Sensorineural hearing loss has been demonstrated in up to
65% of patients receiving cisplatin chemotherapy (Ver-
morken et al., 1983) - 21/60 patients in our study - but a
correlation with peripheral neuropathy has not previously
been reported. We did not find an association with drug
dose.
We confirm the observation that Raynaud's phenomenon
and peripheral neuropathy are frequent late sequelae of testi-
cular cancer chemotherapy but only rarely cause significant
functional impairment (Roth et al., 1988).
Impaired fertility in patients with testicular cancer may be
due to intrinsically abnormal germinal epithelium, the depres-
sant effect of surgery or malignancy, chemotherapy especially
with alkylating agents, irradiation, ejaculatory failure after
retroperitoneal node dissection or psychological problems.
Sperm counts are almost uniformly poor immediately prior
to chemotherapy with correspondingly high levels of FSH
(Drasga et al., 1983; Kreuser et al., 1986). However, within 3
years of cessation of chemotherapy, fertility appears to
recover in about 30-40% of men. Impaired Leydig cell
function has been reported after orchidectomy alone and
after chemotherapy; low levels of testosterone in 25% and
raised LH in almost 50% are quoted (Leitner et al., 1986). In
our study a significant number ofpatients with 1 testis in situ
had subnormal serum testosterone concentrations (23/72) but
only six had low free testosterone index. The effect of
chemotherapy on FSH and LH secretion is not wholly ex-
plicable on the basis of a positive feedback response to low
serum testosterone and it is possible that some of the effect is
centrally mediated, perhaps at the hypothalamic level. The
observed complex endocrine changes require further investi-
gation to separate those attributable to orchidectomy alone,
abnormalities of the remaining testis, and chemotherapy.
Psychological consequences of cancer therapy have until
recently received little attention and this is certainly true of
testicular cancer. Previous studies have conflicted, with claims
by some of an overall psychological benefit from
chemotherapy (Rieker et al., 1985)! Others have confirmed
our finding of rather frequent problems both sexual and
affective (Brenner et al., 1985), although we cannot give an
accurate estimate of their frequency because of the small
number of questionnaires returned - perhaps a reflection of
an absence of problems in the non-responders.
Our data are in agreement with these previous findings but
the high incidence of hypertension which we observed after
chemotherapy remains unexplained and a cause for concern.
While cure of patients with testicular malignancy remains of
paramount importance and treatment must not be compro-
mised to reduce morbidity at the cost ofdisease relapse, close
attention must be paid during follow-up to the late sequelae
of these chemotherapy regimens and particularly their cardio-
vascular, renal and endocrine consequences.
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